Nexalis Therapeutics Details Governance Framework and ASX Compliance

InhaleRx Limited ( (AU:NX1) ) has issued an update.

Nexalis Therapeutics has outlined its corporate governance framework, affirming that its policies and practices materially comply with the 4th edition of the ASX Corporate Governance Council Principles and Recommendations. The board reviews this framework at least annually and has formalised responsibilities via a Board Charter and service contracts for senior management, aiming to maintain clear oversight and accountability.

Given its current size, the company has chosen not to establish separate audit, risk, remuneration, or nomination committees, instead having the full board assume those functions while signalling that sub-committees will be formed as operations expand. Nexalis has also adopted a suite of key governance policies, including on anti-bribery, risk management, securities trading, whistleblowing, and diversity, with the board committed to measurable diversity objectives to strengthen inclusion and stakeholder confidence.

The most recent analyst rating on (AU:NX1) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:NX1 Stock Forecast page.

More about InhaleRx Limited

Nexalis Therapeutics Ltd is an Australian-listed company in the therapeutics sector, focused on developing pharmaceutical or biotech solutions for medical markets. The company operates under the ticker NX1 on the ASX and positions itself as a growth-stage business with a relatively small operational scale, requiring a streamlined governance structure aligned with Australian market standards.

Average Trading Volume: 242,511

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$6.07M

For detailed information about NX1 stock, go to TipRanks’ Stock Analysis page.